Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK2 | O00142 | 9/20 | 0.85 |
| ▸ | TK1 | P04183 | 2/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | BLM | P54132 | 1/20 | 0.64 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.64 |
| ▸ | PYGM | P11217 | 3/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sorivudine SCHEMBL4658822 | 0.92 | TK2 (1.00) | TK2TK1CYP1A2CYP3A4TSHR | |
| Sorivudine SCHEMBL16555084 | 0.92 | TK2 (1.00) | TK2TK1CYP1A2CYP3A4TSHR | |
| Sorivudine SCHEMBL16555082 | 0.92 | TK2 (1.00) | TK2TK1CYP1A2CYP3A4TSHR | |
| Sorivudine SCHEMBL82640 | 0.92 | TK2 (1.00) | TK2TK1CYP1A2CYP3A4TSHR | |
| Sorivudine SCHEMBL3503360 | 0.92 | TK2 (1.00) | TK2TK1CYP1A2CYP3A4TSHR | |
| Sorivudine SCHEMBL13447883 | 0.92 | TK2 (1.00) | TK2TK1CYP1A2CYP3A4TSHR | |
| Sorivudine SCHEMBL4292930 | 0.92 | TK2 (1.00) | TK2TK1CYP1A2CYP3A4TSHR | |
| Sorivudine SCHEMBL13413053 | 0.92 | TK2 (1.00) | TK2TK1CYP1A2CYP3A4TSHR | |
| Sorivudine SCHEMBL1981707 | 0.92 | TK2 (1.00) | TK2TK1CYP1A2CYP3A4TSHR | |
| Sorivudine SCHEMBL5511785 | 0.92 | TK2 (1.00) | TK2TK1CYP1A2CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1284741-B1 | 3'-OR 2'-HYDROXYMETHYL SUBSTITUTED NUCLEOSIDE DERIVATIVES FOR TREATMENT OF VIRAL INFECTIONS | PHARMASSET INC (US) | 2008-11-19 | — | — | EP | disclosed |
| EP-1964569-A2 | 3'-or 2'-hydroxymethyl substituted nucleoside derivatives for treatment of viral infections | Pharmasset, Inc. (US) | 2008-09-03 | — | — | EP | disclosed |
| US-7094770-B2 | 3′-or 2′-hydroxymethyl substituted nucleoside derivatives for treatment of hepatitis virus infections | PHARMASSET, LTD. (BB) | 2006-08-22 | — | — | US | disclosed |
| US-20020055483-A1 | 3'-or 2'-hydroxymethyl substituted nucleoside derivatives for treatment of hepatites virus infections | PHARMASSET, INC. | 2002-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020055483-A1 | 3'-or 2'-hydroxymethyl substituted nucleoside derivatives for treatment of hepatites virus infections | HCCS, HDGF, HMBS | TK2 54/4885TK1 65/4885CYP1A2 305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.